AngioVac Aspiration Thrombectomy of Right Atrial Thrombus is Safe and Effective in Cancer Patients

Callese, Tyler E.; O’Brien, D.; Wilhalme, Holly; Yang, Eric H.; Moriarty, John M.

doi:10.1016/j.avsg.2021.05.057

Cited by 3 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, several case studies have described successful vacuum-assisted embolectomy from the tricuspid valve or right atrial wall in patients with cancer patients [ 108 – 111 ]. Additionally, one small study of 44 patients (20 with active malignancy) suggested that vacuum-assisted thrombectomy may be safe in patients with cancer [ 112 ]. Further investigation of whether percutaneous thrombectomy affects short-term and long-term outcomes is warranted.…”

Section: Venous Thromboembolism Endocarditis and Cancermentioning

confidence: 99%

Interventional Cardio-Oncology: Unique Challenges and Considerations in a High-Risk Population

Leiva

Alam

Bohart

et al. 2023

Curr. Treat. Options in Oncol.

Self Cite

View full text Add to dashboard Cite

Opinion StatementPatients with cancer are at risk of developing cardiovascular disease (CVD) including atherosclerotic heart disease (AHD), valvular heart disease (VHD), and atrial fibrillation (AF). Advances in percutaneous catheter-based treatments, including percutaneous coronary intervention (PCI) for AHD, percutaneous valve replacement or repair for VHD, and ablation and left atrial appendage occlusion devices (LAAODs) for AF, have provided patients with CVD significant benefit in the recent decades. However, trials and registries investigating outcomes of these procedures often exclude patients with cancer. As a result, patients with cancer are less likely to undergo these therapies despite their benefits. Despite the inclusion of cancer patients in randomized clinical trial data, studies suggest that cancer patients derive similar benefits of percutaneous therapies for CVD compared with patients without cancer. Therefore, percutaneous interventions for CVD should not be withheld in patients with cancer, as they may still benefit from these procedures.

show abstract

Section: Venous Thromboembolism Endocarditis and Cancermentioning

confidence: 99%

Interventional Cardio-Oncology: Unique Challenges and Considerations in a High-Risk Population

Leiva

Alam

Bohart

et al. 2023

Curr. Treat. Options in Oncol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…26 Additional smaller studies have shown similar safety and efficacy profiles of AngioVac thrombectomy in the treatment of RHT and CTE. 10,[27][28][29] Treatment of PE with the AngioVac device has been less successful likely due to limited device steerability. 26,27,30…”

Section: Angiovacmentioning

confidence: 99%

Right Heart Clot-in-Transit: Endovascular Therapies

Mathevosian

Ranade

2022

Semin intervent Radiol

View full text Add to dashboard Cite

Right heart thrombus is a challenging high mortality disease typically seen in the setting of pulmonary embolism. Traditional treatments have included anticoagulation, thrombolysis, and surgical embolectomy. Advances in recognition and treatment of clot-in-transit have led to the development of endovascular therapies increasingly becoming the preferred method of treatment due to rapid debulking and lower morbidity. Novel endovascular devices are large bore aspiration thrombectomy systems which mitigate the use of concomitant thrombolytics. The article reviews the disease process, relevant literature, and current endovascular devices and strategies for the treatment of right heart thrombus and clot-in-transit.

show abstract

Navigating the Heart. The Evolution of the AngioVac System in a Single-center Experience

Tarzia

Ponzoni

Tessari

et al. 2023

Current Problems in Cardiology

View full text Add to dashboard Cite

AngioVac Aspiration Thrombectomy of Right Atrial Thrombus is Safe and Effective in Cancer Patients

Cited by 3 publications

References 16 publications

Interventional Cardio-Oncology: Unique Challenges and Considerations in a High-Risk Population

Interventional Cardio-Oncology: Unique Challenges and Considerations in a High-Risk Population

Right Heart Clot-in-Transit: Endovascular Therapies

Navigating the Heart. The Evolution of the AngioVac System in a Single-center Experience

Contact Info

Product

Resources

About